Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Ofgem’s RIIO-3 Sector Specific Methodology Decision
On 18 July 2024, Ofgem published its Sector Specific Methodology Decision (SSMD) for the forthcoming RIIO-3 price control period for electricity transmission (ET), gas transmission (GT) and gas distribution (GD) networks.1 This follows Ofgem’s consultation on the matter in December 2023.2 RIIO-3 will last for… Read More
The future funding of the England & Wales water sector: Ofwat’s draft determinations
On Thursday 11 July, Ofwat (the England and Wales water regulator) published its much anticipated Draft Determinations (DDs). As part of the PR24 price review, this sets out its provisional assessment of allowed revenues and performance targets for AMP8 (2025–30)—and will be of great interest to water companies, investors,… Read More